Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

442 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S, Berglund A, Stattin P. Loeb S, et al. Among authors: stattin p. J Urol. 2013 Nov;190(5):1742-9. doi: 10.1016/j.juro.2013.05.054. Epub 2013 May 30. J Urol. 2013. PMID: 23727309
Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients.
Stattin P, Damber JE, Modig H, Bergh A. Stattin P, et al. Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):885-9. doi: 10.1016/0360-3016(96)00134-4. Int J Radiat Oncol Biol Phys. 1996. PMID: 8751397
p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.
Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE. Stattin P, et al. Eur Urol. 1996;30(1):65-72. doi: 10.1159/000474147. Eur Urol. 1996. PMID: 8854070
Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.
Stattin P, Damber JE, Karlberg L, Bergh A. Stattin P, et al. J Urol. 1997 Jan;157(1):219-22. J Urol. 1997. PMID: 8976256
Prognostic factors in prostate cancer.
Stattin P. Stattin P. Scand J Urol Nephrol Suppl. 1997;185:1-46. Scand J Urol Nephrol Suppl. 1997. PMID: 9249905
Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.
Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE. Stattin P, et al. Eur Urol. 1997;32(4):404-9. Eur Urol. 1997. PMID: 9412796 Clinical Trial.
Evaluation of prognostic factors in prostate cancer with partial least squares analysis.
Wikström P, Wikström P, Lissbrant IF, Bergh A, Damber JE, Stattin P. Wikström P, et al. Among authors: stattin p. Scand J Urol Nephrol. 2000 Aug;34(4):252-6. doi: 10.1080/003655900750041988. Scand J Urol Nephrol. 2000. PMID: 11095083
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Stattin P, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7. doi: 10.1093/jnci/92.23.1910. J Natl Cancer Inst. 2000. PMID: 11106682
Leptin is associated with increased prostate cancer risk: a nested case-referent study.
Stattin P, Söderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, Olsson T. Stattin P, et al. J Clin Endocrinol Metab. 2001 Mar;86(3):1341-5. doi: 10.1210/jcem.86.3.7328. J Clin Endocrinol Metab. 2001. PMID: 11238530
Plasma prolactin and prostate cancer risk: A prospective study.
Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R. Stattin P, et al. Int J Cancer. 2001 May 1;92(3):463-5. doi: 10.1002/ijc.1191. Int J Cancer. 2001. PMID: 11291087
442 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback